Shareholders approved a 40-for-one share consolidation taking effect on October 23, 2026, reducing the number of Class A and Class B ordinary shares by that ratio. The company also increased authorized share capital to US$12.5 million and adopted new articles of association. Additionally, shareholders granted authority for future reverse splits ranging from 10-for-1 to 80-for-1 if the stock price falls below specified thresholds over consecutive trading days. Ping An Biomedical Co., Ltd. operates in the biomedical industry.
